Unibest

Pharmaceutical intermediates

Erlotinib Hydrochloride Intermediates

4 pharmaceutical intermediates for Erlotinib Hydrochloride. Indication: Non-small cell lung cancer; Pancreatic cancer.

Submit a ProjectAll intermediates

About Erlotinib Hydrochloride

Originator
Genentech
Indication
Non-small cell lung cancer; Pancreatic cancer
Approved Date
11/18/2004

Available intermediates

4 intermediates currently listed for Erlotinib Hydrochloride. Request specifications, documentation or a quotation for any item below.

Erlotinib Hydrochloride intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
3-Ethynylaniline54060-30-9//
6,7-Bis-(2-methoxyethoxy)-4(3H)-quinazolinone179688-29-0//
2-Amino-4,5-bis(2-methoxyethoxy)benzoic acid ethyl ester hydrochloride183322-17-0//
4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline183322-18-1//

Other programs under E

Edoxaban tosylate monohydrateElacestrantElagolix SodiumEldecalcitolElinzanetantElobixibatEltrombopagEltrombopag Olamine

Building toward Erlotinib Hydrochloride?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

Submit a Project Talk to the team

How can we help you?

Receive insights into the latest events and regulatory updates

Sent directly to your email

Get industry insights and Unibest news here

Contact Us →